A Rare Large Cell Neuroendocrine Carcinoma in a 72-year-old Man

Teodora Amor N. Evora and Michael L. Villa

Section of Endocrinology and Metabolism, Department of Internal Medicine,
St. Luke's Medical Center, Quezon City, Philippines

A 72-year-old male, previous smoker presented with cough and shortness of breath of one week duration. His chest x-ray showed linear densities in the right paracardiac and both lung bases. Contrast-enhanced CT scan uncovered multiple, enlarged soft tissue masses in the pretracheal, right paratracheal, subcarinal and right paravertebral regions (Figure 1). There were also reticular ground glass opacities scattered in both lung bases and periphery. No endobronchial mass was seen. The thyroid, adrenal glands, pancreas, liver and the rest of the viscera organs were normal. Mediastinoscopy with excision biopsy was done. Microscopic examination revealed large tumor cells arranged in solid sheets or nests (Figure 2). The differential diagnosis included diffuse large cell lymphoma and poorly-differentiated carcinoma believed to be primary lung versus mediastinal cancer. Positive immunohistochemical staining of tumor cell cytoplasm for Chromogranin, Synaptophysin, and CD 56 (Figure 3), and negative for cytokeratins confirmed the diagnosis of Large Cell Neuroendocrine carcinoma. Whole body $^{18}$F-Fluorodeoxyglucose (FDG) PET-CT scan was done to locate the primary tumor and delineate the extent of disease. There was a mildly enhancing 1.3 x 1.3 cm mass

Figure 1. Contrast-enhanced chest CT scan demonstrating multiple, enlarged lymph nodes in the (A) pretracheal (arrow), (B) prevertebral (arrow), and (C) subcarinal (arrow) regions.

ISSN 0987-8074
Copyright © 2011 by the JAFES
Received September 16, 2010. Accepted February 10, 2011.

Corresponding author: Teodora Amor N. Evora, M.D.
Diabetes, Thyroid and Endocrine Center
2nd fl., Cathedral Heights Building,
St. Luke's Medical Center, E. Rodriguez Ave.,
Quezon City, Philippines
Tel. No. 7230101 (Local 5310)
Fax No. 7230101 (Local 5210)
Mobile No.: 0922-8372185

Vol. 26 No. 2 November 2011 www.asean-endocrinejournal.org 179
in the right temporal lobe with FDG uptake similar to that of white matter. The previously seen mediastinal and right hilar lymphadenopathies had intense FDG uptake with standardized uptake value (SUV) up to 7.3 g/ml (Figure 4). In contrast, the previously noted reticular ground glass opacities in both lungs had low-grade uptake on PET. There were multiple hypermetabolic lesions in both hepatic lobes with SUV up to 5.4 g/ml (Figure 5) which appeared normal on the initial CT scan. A 24-hour urinary 5-hydroxyindoleacetic acid (5HIAA) was four times elevated, indicative of tumor secretory activity. He underwent chemotherapy with Carboplatin, Etoposide and Topotecan and radiation therapy with complete disappearance of the brain lesion but with further derangement in liver function.

Neuroendocrine tumors (NET) are rare, solid malignant tumors that arise from dispersed neuroendocrine cells found throughout the body. According to the 2004 analysis of Surveillance, Epidemiology and End Results (SEER) database, the age-adjusted incidence of NET is of 5.25 cases per 100,000 people. The majority of NETs arise within the gastroenteropancreatic system while the bronchial tract represents the second most frequent primary site. NETs with an undetected primary tumor have been noted in more than 4% of cases in several studies. A primary tumor site could not be found in 4,753 (13%) out of 35,618 NET in the SEER database analysis. NETs may produce a variety of clinical syndromes depending on a multitude of peptides and hormones being secreted. However, most NETs are clinically silent or elicit non-specific symptoms such that diagnosis is often delayed and with metastatic disease at presentation.

The cornerstone of diagnosis of NET is histopathology including immunohistochemistry. Immunohistochemistry is most important for verification of the neuroendocrine nature of the tumor. It is also crucial in characterizing the proliferative potential of the tumor because this has been shown to be of prognostic value. Chromogranin A and/or Synaptophysin positivity are considered sufficient for the diagnosis. A 24 hr urine 5HIAA is a good biomarker of tumor secretory activity and may be predictive of reduced survival.

Several imaging techniques are available for localization of tumor and monitoring disease progression. Somatostatin Receptor Scintigraphy (SRS) has a high sensitivity of 86-95% and should be the initial imaging procedure to localize and establish the stage of disease. However, the difficulty and expense of obtaining an SRS is prohibitive. FDC-PET scanning may be useful in finding a primary tumor and identifying poorly-differentiated anaplastic tumor.

Treatment of metastatic neuroendocrine carcinoma of unknown primary site depends on the pathologic categorization as to whether the tumor is well-to moderately differentiated (large cell tumors) or poorly differentiated (high grade, anaplastic, small cell tumors). SRS is carried out to indicate the presence of somatostatin receptors and imply likelihood to respond to a long-acting somatostatin analogue. If the SRS is negative, other treatment options include hepatic artery chemoeembolization (HACE), radioactive microspheres (SIRS) therapy, or conventional chemotherapy considering some of the newer agents, such as tyrosine kinase inhibitors.

Our patient presented with a rare Large Cell Neuroendocrine carcinoma that has metastasized to the mediastinal and hilar lymph nodes, liver and brain but whose primary tumor was undetected. A possible primary lung cancer was highly considered. There was tumor

Figure 2. Photomicrographs of a mediastinal lymph node exhibiting (A) proliferation of tumor cells arranged in a diffuse nest pattern (H&E, 40x magnification); and (B) tumor cells with enlarged hyperchromatic and pleomorphic nuclei (arrows) and scanty cytoplasm (H&E, 400x magnification).
progression 2 months after chemotherapy and radiation therapy. Our case may benefit from a SRS for further tumor localization and likelihood to respond to somatostatin analogue.

References